UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer

Annals of oncology, 2011-08, Vol.22 (8), p.1798-1804

2011

Volltextzugriff (PDF)

First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours

European journal of cancer (1990), 2017-07, Vol.80, p.14-25

2017

Volltextzugriff (PDF)

Localablative treatment for synchronous oligometastatic lung cancer: A propensity score analysis of 180 patients

Annals of oncology, 2018-10, Vol.29, p.viii536-viii536

2018

Volltextzugriff (PDF)

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

Annals of oncology, 2012-08, Vol.23 (8), p.1979-1985

2012

Volltextzugriff (PDF)

Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy

Annals of oncology, 2011-03, Vol.22 (3), p.657-663

2011

Volltextzugriff (PDF)

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer

Annals of oncology, 2006-04, Vol.17 (4), p.663-667

2006

Volltextzugriff (PDF)

High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma

Annals of oncology, 2005-03, Vol.16 (3), p.445-449

2005

Volltextzugriff (PDF)

Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy

Bone marrow transplantation (Basingstoke), 2011-06, Vol.46 (6), p.840-846

2011

Volltextzugriff (PDF)

A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma

Annals of oncology, 2006-12, Vol.17 (12), p.1826-1829

2006

Volltextzugriff (PDF)

Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment

Annals of oncology, 2004-08, Vol.15 (8), p.1237-1242

2004

Volltextzugriff (PDF)

614 First-in-man Dose Escalation and Pharmacokinetic Study of CAP7.1, a Novel Etoposide Prodrug in Adults with Heavily Pretreated Solid Tumors

European journal of cancer (1990), 2012-11, Vol.48, p.189-189

2012

Volltextzugriff (PDF)

Prognostic Relevance of Circulating Tumor Cells in Metastatic Uveal Melanoma

Oncology, 2011-01, Vol.80 (1-2), p.57-62

2011

Volltextzugriff (PDF)

Monitoring of circulating tumor cells in a patient with synchronous metastatic melanoma and colon carcinoma

Annals of oncology, 2010-08, Vol.21 (8), p.1734-1735

2010

Volltextzugriff (PDF)

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer

Cancer research (Chicago, Ill.), 2000-09, Vol.60 (17), p.4850-4854

2000

Volltextzugriff (PDF)

Neomycin as secondary prophylaxis for irinotecan-induced diarrhea

Annals of oncology, 2004-08, Vol.15 (8), p.1296-1296

2004

Volltextzugriff (PDF)

First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology

European respiratory review, 2014-03, Vol.23 (131), p.92-105

2014

Volltextzugriff (PDF)

Abstract No. 184: Transarterial Chemoembolization (TACE) of Liver Metastases from Uveal Melanoma: Evaluation of Efficacy and LDH as a Prognostic Factor

Journal of vascular and interventional radiology, 2009, Vol.20 (2), p.S71-S71

2009

Volltextzugriff (PDF)

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma

Annals of oncology, 2006-12, Vol.17 (12), p.1830-1834

2006

Volltextzugriff (PDF)

Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population

Annals of oncology, 2019-10, Vol.30, p.v615

2019

Volltextzugriff (PDF)

1499P - Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population

Annals of oncology, 2019-10, Vol.30, p.v615-v615

2019

Volltextzugriff (PDF)

1499PPembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Complementary and Alternative Medicine in Lung Cancer Patients: A Neglected Phenomenon?

Frontiers of radiation therapy and oncology, 2010-01, Vol.42, p.198-205

2010

Volltextzugriff (PDF)

1482PLocalablative treatment for synchronous oligometastatic lung cancer: A propensity score analysis of 180 patients

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Lipopolysaccharide Effectively Up‐Regulates B7‐1 (CD80) Expression and Costimulatory Function of Human Monocytes

Scandinavian journal of immunology, 1995-12, Vol.42 (6), p.701-704

1995

Volltextzugriff (PDF)

Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6747-6755

2005

Volltextzugriff (PDF)

1 – 25 von 750

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(626)
Mit Volltextzugriff
(664)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer

First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours

Localablative treatment for synchronous oligometastatic lung cancer: A propensity score analysis of 180 patients

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer

High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma

Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy

A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma

Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment

614 First-in-man Dose Escalation and Pharmacokinetic Study of CAP7.1, a Novel Etoposide Prodrug in Adults with Heavily Pretreated Solid Tumors

Prognostic Relevance of Circulating Tumor Cells in Metastatic Uveal Melanoma

Monitoring of circulating tumor cells in a patient with synchronous metastatic melanoma and colon carcinoma

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer

Neomycin as secondary prophylaxis for irinotecan-induced diarrhea

First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology

Abstract No. 184: Transarterial Chemoembolization (TACE) of Liver Metastases from Uveal Melanoma: Evaluation of Efficacy and LDH as a Prognostic Factor

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma

Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population

1499P - Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population

1499PPembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population

Complementary and Alternative Medicine in Lung Cancer Patients: A Neglected Phenomenon?

1482PLocalablative treatment for synchronous oligometastatic lung cancer: A propensity score analysis of 180 patients

Lipopolysaccharide Effectively Up‐Regulates B7‐1 (CD80) Expression and Costimulatory Function of Human Monocytes

Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

Suchergebnisse filtern